Search research articles
Contact Us
Filters
Showing results (81-90 of 231) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics
Laura Rosiñol, Albert Oriol, Maria Victoria Mateos, et al.
Journal of Clinical Pharmacology
|
November 4, 2020
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Man Melody Luo, Saad Z Usmani, Maria-Victoria Mateos, et al.
Haematologica
|
November 9, 2014
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Bruno Paiva, Mauricio Chandia, Noemi Puig, et al.
Cancer Medicine
|
February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Haematologica
|
August 30, 2023
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Luděk Pour, Monika Szarejko, Jelena Bila, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.
Cancer
|
March 30, 2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Thomas G Martin, Maria Victoria Mateos, Ajay Nooka, et al.
Blood Cancer Journal
|
August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
Charlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
Blood Advances
|
November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
Thierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Maria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
Page
of 24
Search research articles
Search
Showing results (81-90 of 231) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics
Laura Rosiñol, Albert Oriol, Maria Victoria Mateos, et al.
Journal of Clinical Pharmacology
|
November 4, 2020
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Man Melody Luo, Saad Z Usmani, Maria-Victoria Mateos, et al.
Haematologica
|
November 9, 2014
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Bruno Paiva, Mauricio Chandia, Noemi Puig, et al.
Cancer Medicine
|
February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Haematologica
|
August 30, 2023
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Luděk Pour, Monika Szarejko, Jelena Bila, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.
Cancer
|
March 30, 2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Thomas G Martin, Maria Victoria Mateos, Ajay Nooka, et al.
Blood Cancer Journal
|
August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
Charlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
Blood Advances
|
November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
Thierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Maria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
Page
of 24